Huntington's disease

Teva gains FDA approval for once-daily formulation of flagship drug Austedo
Teva gains FDA approval for once-daily formulation of flagship drug Austedo
Fierce Pharma
Teva Pharmaceutical
FDA
Austedo
tardive dyskinesia
Huntington's disease
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Huntington's Disease Continues to Baffle Biopharma
Huntington's Disease Continues to Baffle Biopharma
BioSpace
Huntington's disease
Triplet Therapeutics
PTC Therapeutics
Flag link:
UniQure revs up engines again for Huntington's gene therapy after trial hospitalizations
UniQure revs up engines again for Huntington's gene therapy after trial hospitalizations
Fierce Biotech
uniQure
Huntington's disease
gene therapy
AMT-130
Flag link:
Teva reports data from Huntington’s disease-linked chorea trial
Teva reports data from Huntington’s disease-linked chorea trial
Clinical Trials Arena
Teva Pharmaceutical
Austedo
clinical trials
chorea
Huntington's disease
Flag link:
NeuBase Abandons Huntington's, 60% of Workforce in Strategic Pivot
NeuBase Abandons Huntington's, 60% of Workforce in Strategic Pivot
BioSpace
NeuBase
Huntington's disease
layoffs
Flag link:
Atlas-backed biotech focused on Huntington's disease shuts down less than three years after launch
Atlas-backed biotech focused on Huntington's disease shuts down less than three years after launch
Endpoints
Triplet Therapeutics
Huntington's disease
Flag link:
Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
BioPharma Dive
Novartis
Huntington's disease
clinical trials
branaplam
Flag link:
BrainVectis gains approval for Phase I/II Huntington’s gene therapy trial
BrainVectis gains approval for Phase I/II Huntington’s gene therapy trial
Clinical Trials Arena
AskBio
BrainVectis
clinical trials
Huntington's disease
Flag link:
uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered
uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered
Fierce Biotech
uniQure
clinical trials
Huntington's disease
AMT-130
Flag link:
uniQure shares spike as investors see bright spot in 12-month Huntington's gene therapy data
uniQure shares spike as investors see bright spot in 12-month Huntington's gene therapy data
Fierce Biotech
uniQure
Huntington's disease
gene therapy
AMT-130
Flag link:
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening
BioSpace
bit.bio
Huntington's disease
ioDisease Model
drug discovery
Flag link:
Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.
Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.
BioPharma Dive
Roche
clinical trials
Huntington's disease
Flag link:
Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial
Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial
Fierce Biotech
Roche
Ionis Pharmaceuticals
tominersen
Huntington's disease
clinical trials
Flag link:
Annexon becomes the latest group to provide a confusing update in Huntington's disease
Annexon becomes the latest group to provide a confusing update in Huntington's disease
EP Vantage
Annexon Biosciences
Huntington's disease
clinical trials
ANX005
Flag link:
A high-profile gene therapy biotech takes aim at Huntington's
A high-profile gene therapy biotech takes aim at Huntington's
BioPharma Dive
Passage Bio
gene therapy
Huntington's disease
Flag link:
Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry
Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry
MedCity News
Origami Therapeutics
protein degradation
neurodegenerative disease
Huntington's disease
Flag link:
Roche, hoping to move on from recent failure, pens $190M NeuExcell Huntington's disease pact
Roche, hoping to move on from recent failure, pens $190M NeuExcell Huntington's disease pact
Fierce Biotech
Roche
Huntington's disease
NeuExcell
Flag link:
8 key clinical trials to watch for the rest of 2021
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
clinical trials
Merck
Ridgeback Biotherapeutics
COVID-19
Intellia Therapeutics
transthyretin amyloidosis
Arcus Biosciences
Gilead Sciences
lung cancer
Sanofi
GSK
vaccines
uniQure
Huntington's disease
Mirati Therapeutics
gene editing
Seres Therapeutics
ulcerative colitis
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
UniQure moves Huntington's gene therapy to next phase of key trial
UniQure moves Huntington's gene therapy to next phase of key trial
BioPharma Dive
uniQure
Huntington's disease
clinical trials
gene therapy
AMT-130
Flag link:

Pages